Peptides for Energy: A Look at Mitochondrial Power

Several classes of peptides, both naturally produced by mitochondria and synthetically designed, can influence how efficiently your cells generate energy. Mitochondria encode their own small signaling peptides that regulate metabolism, protect energy-producing machinery from damage, and even communicate with the cell’s nucleus during stress. Meanwhile, lab-designed peptides target the inner mitochondrial membrane to restore energy output in damaged tissues. The science is still young, but the picture emerging from cell studies, animal models, and early clinical trials suggests that these tiny molecules sit at a surprisingly important intersection of metabolism, aging, and disease.

A Quick Look at How Mitochondria Make Energy

Your mitochondria convert the food you eat into a molecule called ATP, the universal energy currency your cells spend on everything from muscle contraction to brain signaling. The process relies on a chain of protein complexes embedded in the inner mitochondrial membrane. Electrons shuttle through these complexes, and in the process, protons get pumped across the membrane to build up an electrochemical gradient. That gradient then drives a rotating molecular motor, ATP synthase, which snaps a phosphate group onto ADP to create ATP.^{1 2} When any part of this chain falters, energy production drops, damaging byproducts called reactive oxygen species accumulate, and cells start to struggle. This is where peptides enter the story.

Mitochondrial-Derived Peptides Are a New Category of Signaling Molecule

For a long time, scientists viewed the mitochondrial genome as a minimalist operation: it codes for 13 proteins, all of which are subunits of the energy-producing chain. But researchers have discovered that hidden within the mitochondrial DNA are small open reading frames encoding tiny bioactive proteins now called mitochondrial-derived peptides, or MDPs. Eight of these have been characterized so far, including humanin, MOTS-c, and a family of six called SHLPs (small humanin-like peptides). Each modifies cell metabolism in distinct ways, and collectively they have shown protective effects in models of diabetes, cardiovascular disease, neurodegeneration, and cancer.³ Researchers suspect hundreds more MDPs remain undiscovered, which would reshape how we understand mitochondrial communication with the rest of the cell.

The broader concept here is “retrograde signaling,” the idea that mitochondria are not passive energy factories waiting for instructions from the nucleus. They actively send molecular messages back to the cell, influencing gene expression, stress responses, and metabolic decisions. MDPs appear to be a major channel for this communication.

MOTS-c and Metabolic Regulation

Of all the known MDPs, MOTS-c has attracted the most attention for its effects on energy metabolism. In cell studies, treating cells with MOTS-c activates AMPK, an enzyme often described as the cell’s fuel gauge. When AMPK switches on, it ramps up fatty acid burning and glucose uptake in muscle, essentially telling the cell to produce and consume more energy.⁴ This makes intuitive sense as an energy-boosting signal: if the mitochondria sense metabolic stress, they release MOTS-c, which then pushes the cell to mobilize more fuel.

What makes MOTS-c especially interesting is that it does not just act locally. Under metabolic stress, the peptide travels from the mitochondria into the cell nucleus, where it directly influences gene expression. There, it interacts with stress-responsive transcription factors and activates genes involved in antioxidant defense.⁵ So MOTS-c is doing double duty: it boosts energy production through AMPK and simultaneously protects the cell from the oxidative damage that higher energy output can cause. That nuclear translocation has been confirmed with both the cell’s own endogenous MOTS-c and with synthetically administered versions of the peptide.⁶

Exercise Triggers MOTS-c in Humans

If you have ever wondered whether your body already uses these peptides during physical activity, the answer is yes. Researchers measured MOTS-c levels in people before, during, and after exercise and found dramatic increases. In skeletal muscle, endogenous MOTS-c levels rose roughly 12-fold after exercise and climbed even higher, to about 19-fold, after four hours of rest. Circulating levels in the blood also increased during and after exercise, though more modestly, before returning to baseline.⁷

This finding reframes exercise at the molecular level. Part of why physical activity improves metabolic health may be that it prompts mitochondria to release signaling peptides like MOTS-c, which then coordinate a whole-body metabolic tune-up. The post-exercise increase persisting at four hours suggests these peptides are not just a momentary spike during exertion but part of a sustained adaptive response. It also raises a provocative question: could administering MOTS-c replicate some metabolic benefits of exercise for people who cannot exercise due to illness or disability? That possibility is being explored in animal research, though human trials remain in early stages.

Humanin and SHLP2 Protect the Energy Machinery

Humanin was the first MDP discovered, initially identified for its ability to protect neurons from cell death in Alzheimer’s disease models. Since then, its protective reach has expanded considerably. Humanin shields cells from oxidative stress, low oxygen, and nutrient deprivation, and it has shown benefits in animal models of cardiovascular disease and neurodegeneration.⁸ Its relevance to energy is indirect but important: by preventing the cellular damage that degrades mitochondrial function, humanin helps maintain the conditions under which energy production can proceed normally.

SHLP2, one of the small humanin-like peptides, provides a more direct link to mitochondrial energy output. In a study using cell models of age-related macular degeneration, where mitochondria are known to be compromised, SHLP2 treatment dramatically increased levels of all five protein complexes in the energy-producing chain. Complex I subunit levels surged by about 350%, Complex IV by roughly 220%, and the other complexes saw increases ranging from about 30% to 55%. The treatment also improved cell survival by about 22%.⁹ Those numbers are from a cell model, not a human clinical trial, so they should be read as proof of concept rather than a guaranteed therapeutic effect. But the implication is striking: a peptide encoded in mitochondrial DNA can, at least in diseased cells, restore the very protein machinery that mitochondria need to make ATP.

SS-31, a Synthetic Peptide That Targets Cardiolipin

Not all energy-boosting peptides come from the mitochondria themselves. SS-31, also known as elamipretide, is a short synthetic peptide designed to home in on the inner mitochondrial membrane. It works by binding to cardiolipin, a specialized lipid found almost exclusively on that membrane. Cardiolipin is essential for maintaining the structure of the folds (cristae) where the energy-producing complexes sit, and it plays a direct role in organizing those complexes for efficient electron transport.¹⁰

When mitochondria are stressed, cardiolipin gets oxidized and damaged, which disrupts the membrane architecture and tanks energy production. SS-31 binds cardiolipin and protects it from this oxidative damage. Research also shows that SS-31 modulates the surface charge of mitochondrial membranes in ways that reduce the energy burden of calcium stress, a common contributor to mitochondrial dysfunction in conditions like heart failure and kidney injury.¹¹

SS-31 has advanced further toward the clinic than any MDP. A randomized, placebo-controlled trial tested a single infusion of elamipretide in patients with heart failure and reduced ejection fraction. The high dose produced favorable changes in heart volume that correlated with peak plasma concentrations, suggesting a real dose-effect relationship. The infusion was safe and well tolerated, though the trial was designed to assess safety rather than long-term benefit.¹² Larger trials are still needed to determine whether repeated dosing translates into durable improvements in heart function and energy levels for patients.

Growth Hormone Secretagogues and Mitochondrial Biogenesis

A somewhat different route to boosting mitochondrial energy involves peptides that stimulate growth hormone release. Hexarelin and related growth hormone-releasing peptides do not target the mitochondria directly. Instead, they appear to trigger a cascade that ultimately activates PGC-1α, widely considered the master regulator of mitochondrial biogenesis, the process by which cells build new mitochondria. In a rat model of muscle wasting caused by the chemotherapy drug cisplatin, treatment with hexarelin and a related compound called JMV2894 boosted PGC-1α levels and helped protect skeletal muscle mitochondria from damage.¹³

Hexarelin has also shown effects on fat cells. In white adipocytes, hexarelin treatment depleted intracellular fat stores and increased markers normally associated with brown fat, including the thermogenic protein UCP-1 and PGC-1α itself.¹⁴ Brown fat is metabolically active tissue that burns calories to generate heat, and the shift toward a brown fat-like profile in white fat cells suggests hexarelin may push cells toward higher energy expenditure. This is a fundamentally different strategy from what MDPs or SS-31 do. Rather than repairing or protecting existing mitochondria, growth hormone secretagogues encourage cells to make more of them.

Why Mitochondrial Peptides Decline With Age

One of the more sobering findings in this field is that your body’s own production of these protective peptides drops as you get older. Circulating levels of both humanin and SHLP2 decline with age.¹⁵ This decline tracks uncomfortably well with the broader deterioration in mitochondrial function that characterizes aging. As you age, mitochondrial DNA accumulates mutations, the energy-producing complexes become less efficient, and reactive oxygen species production creeps upward. If the peptides that normally counteract these problems are also dwindling, you get a compounding effect: less protection at exactly the time you need more.

Clinical studies have linked reduced mitochondrial activity to fat accumulation inside muscle cells, insulin resistance, and impaired ability to switch between burning fat and sugar. These metabolic problems are hallmarks of both obesity and type 2 diabetes, and they worsen with age. The decline in mitochondrial peptide levels may be one mechanism, among several, connecting aging to metabolic disease. Whether supplementing these peptides externally could slow that trajectory is one of the central questions researchers are now pursuing.

The Delivery Problem

Even if a peptide has impressive effects in cell culture or animal studies, getting it to work reliably in a human body is a separate challenge. Peptides are inherently fragile molecules. They lack the complex three-dimensional structure that protects larger proteins, which leaves them vulnerable to rapid breakdown by enzymes in the blood and gut. Most are cleared quickly by the kidneys, resulting in short half-lives and reduced effectiveness.¹⁶ This is why the vast majority of approved peptide drugs require injection rather than oral dosing.¹⁷

For mitochondria-targeted peptides, there is an additional layer of difficulty: the peptide has to not only survive in the bloodstream and enter cells, but then navigate to the mitochondria specifically and, in some cases, penetrate the inner membrane to reach the matrix. Researchers are developing bifunctional hybrid peptides that fuse a mitochondrial targeting sequence with a cell-penetrating peptide to address this. Early work shows the approach can get cargo into the mitochondrial matrix, but the choice of targeting sequence matters a great deal; not every combination works equally well.¹⁷ Other groups have built on the structure of SS-31 itself to design unusually small cell-penetrating peptides that preferentially accumulate in mitochondria.¹⁸

This delivery bottleneck is worth keeping in mind when you encounter breathless marketing about “mitochondrial peptide supplements.” A peptide that rescues energy production in cultured cells faces a gauntlet of enzymatic degradation, poor absorption, and subcellular misdirection before it reaches the organelle it is supposed to help. Injection-based delivery under clinical conditions is one thing; swallowing a capsule and hoping it survives to reach your mitochondria is quite another.

Mitohormesis and the Stress Connection

An idea gaining traction in this field is mitohormesis: the principle that moderate mitochondrial stress can actually make cells healthier in the long run. When mitochondria encounter low-level stress, they activate repair programs that leave the cell more resilient than it was before. The mitochondrial stress response and a related pathway called the mitochondrial unfolded protein response are both thought to work this way, promoting cellular repair mechanisms that improve stress resistance and metabolic health outcomes.¹⁹

MDPs fit neatly into this framework. MOTS-c, for instance, is released in response to metabolic stress and then orchestrates a coordinated defense involving both metabolic and antioxidant genes. Rather than simply flooding the cell with energy, it helps the cell adapt to the stress that triggered the signal in the first place. This is consistent with the exercise data: physical activity is a form of metabolic stress, and the MOTS-c surge that follows may be one way the body converts that stress into long-term benefit. If researchers can learn to harness mitohormesis pharmacologically, the goal would not be to eliminate mitochondrial stress entirely but to mimic the kind of controlled stress that triggers beneficial adaptation.

Dietary Restriction and Endogenous Peptide Production

Caloric restriction is one of the most reliable ways to improve mitochondrial function in animal models, and there are hints that it works partly through the same signaling channels that MDPs use. When cells are deprived of certain amino acids, they ramp up hydrogen sulfide production through specific enzymatic pathways. This response has been observed both in living animals and in isolated liver cells cultured without sulfur-containing amino acids.²⁰ Hydrogen sulfide, at low concentrations, is itself a signaling molecule that influences mitochondrial function and has been linked to the longevity benefits of dietary restriction.

The overlap between dietary restriction pathways and MDP signaling is still being mapped, but it points to a broader pattern: your mitochondria are exquisitely sensitive to nutrient availability, and the peptides they produce are part of how they communicate that information to the rest of the cell. This suggests that strategies to boost mitochondrial energy do not begin and end with pharmaceutical peptides. Nutritional inputs, exercise habits, and the timing of meals all feed into the same signaling networks. A peptide supplement, however sophisticated, would operate alongside those signals rather than in place of them.